Sign In
Buy BBP
$84.48
+0.92 (+1.10%)
At Close: Jun 03, 2026
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
07:30am, Wednesday, 27'th May 2026
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for tr
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
07:30am, Monday, 30'th Mar 2026
- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
02:00pm, Wednesday, 11'th Mar 2026
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
07:00am, Monday, 27'th Oct 2025
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company's prior studies
PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically significant change, in contrast to the
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
04:45pm, Tuesday, 10'th Sep 2024
- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812
4 Best-Performing Sector ETFs of June
05:10am, Tuesday, 02'nd Jul 2024
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Biotech ETFs Stage Solid Comeback at the Start of 2024
12:47pm, Tuesday, 09'th Jan 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-
5 Least-Hurt Biotech ETFs of the Last Week
02:18pm, Wednesday, 15'th Feb 2023
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Can Health Care Stocks Outperform Again In 2023?
06:09pm, Wednesday, 11'th Jan 2023
How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.
2 Sector ETFs Hovering Around a 52-Week High
02:18pm, Tuesday, 06'th Dec 2022
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
5 Best Areas of Q3 of 2022 & Their Top ETFs
09:02am, Tuesday, 27'th Sep 2022
These ETF areas won in the third quarter of 2022.
Biotech & Crypto -- Best ETF Areas of Last Week
03:48pm, Monday, 08'th Aug 2022
Biotech and cryptocurrency -- two ETF areas outperformed last week.
